Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA9 | Q16790 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307735 | 0.98 | TSHR (0.47) | TSHRCA1CA9CA12CA2 | |
| SCHEMBL5404185 | 0.96 | TSHR (0.46) | TSHRCA1CA9CA12CA2 | |
| SCHEMBL28320390 | 0.85 | ALDH1A1 (0.52) | TSHRCA1CA9TDP1MEN1 | |
| SCHEMBL27828903 | 0.82 | TSHR (0.54) | TSHRTDP1LMNAALDH1A1HSD17B10 | |
| SCHEMBL6553295 | 0.82 | TSHR (0.50) | TSHRMEN1KMT2ALMNAALDH1A1 | |
| Fluoride SCHEMBL28135103 | 0.80 | TSHR (0.48) | TSHRMEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL9770279 | 0.79 | TSHR (0.57) | TSHRCA1CA9CA12CA2 | |
| SCHEMBL9770256 | 0.79 | TSHR (0.57) | TSHRCA1CA9CA12CA2 | |
| SCHEMBL59256 | 0.79 | TSHR (0.57) | TSHRCA1CA9CA12CA2 | |
| SCHEMBL11298207 | 0.79 | TSHR (0.57) | TSHRCA1CA9CA12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946028-B | Synthesis method of 1, 4-benzothiazepine compound | 南通大学 | 2024-09-24 | — | — | CN | claimed |
| CN-117946028-A | Synthesis method of 1, 4-benzothiazepine compound | 南通大学 | 2024-04-30 | — | — | CN | claimed |
| CN-117946028-B | Synthesis method of 1, 4-benzothiazepine compound | 南通大学 | 2024-09-24 | — | — | CN | disclosed |
| CN-117946028-A | Synthesis method of 1, 4-benzothiazepine compound | 南通大学 | 2024-04-30 | — | — | CN | disclosed |
| CN-114815428-B | Photochromic materials | 惠州市华阳光学技术有限公司 | 2024-04-26 | — | — | CN | disclosed |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| CN-114815428-A | Photochromic material | 惠州市华阳光学技术有限公司 | 2022-07-29 | — | — | CN | disclosed |
| EP-3943500-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | Agilent Technologies, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | UNIVERSITY OF COLORADO BOULDER | 2022-01-06 | — | — | US | disclosed |
| EP-3137478-B1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | AGILENT TECHNOLOGIES INC (US) | 2021-09-22 | — | — | EP | disclosed |
| CN-106255697-B | Phosphorus protecting group and preparation method and application thereof | 安捷伦科技有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-1342091-A | Combinations of cardiovascular indications | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1342089-A | Combinations of ileal bile acid transport inhibitors and cholestery ester transfer protein inhibitors for cardiovascular disease | SEARLE & CO (US) | 2002-03-27 | — | — | CN | disclosed |
| CN-1338944-A | Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications | SEARLE & CO (US) | 2002-03-06 | — | — | CN | disclosed |
| WO-2001049275-A2 | METHODS AND COMPOSITIONS FOR MITIGATING PAIN USING NITRATE ESTERS | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2001-07-12 | — | — | WO | disclosed |
| CN-1296940-A | Environmentally friendly process for preparing benzoic acid and its derivatives | SHANGHAI INST ORGANIC CHEM (CN) | 2001-05-30 | — | — | CN | disclosed |
| CN-1060644-C | Dental composition for relieving dentin hypersensitivity | SUN MEDICAL CO LTD (JP) | 2001-01-17 | — | — | CN | disclosed |
| CN-1130500-A | Dental composition for relieving dentin hypersensitivity | SUN MEDICAL CO LTD (JP) | 1996-09-11 | — | — | CN | disclosed |
| US-5021491-A | Heat stabilizers for thermoplastic chloropolymers | CIBA-GEIGY CORPORATION (US) | 1991-06-04 | — | — | US | disclosed |
| CN-1046848-A | Phospholipid-water preparation and its production and application | NATTERMANN A & CIE (DE) | 1990-11-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220002334-A1 | PHOSPHOROUS PROTECTING GROUPS AND METHODS OF PREPARATION AND USE THEREOF | POLN, POLRMT, NUDT21 | TSHR 3949/4885CA1 3613/4885CA9 2496/4885 |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | TSHR 3949/4885CA1 3613/4885CA9 2496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.